Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome
Norman Gaylis, Angela Ritter, Scott A. Kelly, Nader Pourhassan, Meenakshi Tiwary, Jonah B. Sacha, Scott G. Hansen, Christopher Recknor, Otto O. Yang
Abstract
In an exploratory trial treating "long COVID" with the CCR5-binding antibody leronlimab, we observed significantly increased blood cell surface CCR5 in treated symptomatic responders but not in nonresponders or placebo-treated participants. These findings suggest an unexpected mechanism of abnormal immune downmodulation in some persons that is normalized by leronlimab. Clinical Trials Registration. NCT04678830.
Topics & Concepts
MedicineImmunosuppressionCoronavirus disease 2019 (COVID-19)ImmunologyClinical trialImmune systemAntibodyPlaceboChemokine receptorChemokineDiseaseInternal medicineInfectious disease (medical specialty)PathologyAlternative medicineLong-Term Effects of COVID-19COVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 Research